The DOI matches its Crossref record.
Lessons from the rotenone model of Parkinson's disease
Open accessAbstract
In their recent review on environmental toxins and Parkinson’s disease (PD)1, under the heading ‘What have we learned from the Rotenone model of PD?’, Cicchetti and colleagues do not list a single positive aspect of the model. It is possible, however, to view the rotenone model from a different perspective. Rotenone was first used to model PD in 1985 when Heikkila injected this mitochondrial complex I inhibitor directly into the brain and showed that at a concentration of 5 mM – approximately 500,000-fold higher than its IC50 of 10 nM – it killed dopaminergic neurons2; however, identical results could have been obtained with a high concentration of virtually any toxin, mitochondrial or otherwise. Later, because there was a growing suspicion that PD might be associated with systemic mitochondrial defects, several groups began to experiment with systemic administration of mitochondrial toxins. Ferrante (1997) reported that administration of rotenone (10-18 mg/kg/day) produced ‘nonspecific’ brain lesions and peripheral toxicity3. In contrast, when Betarbet (2000) titrated the experimental complex I inhibition to a level similar to that reported in platelets from PD patients (using 2-3 mg/kg/day), it produced highly selective nigrostriatal degeneration4. Even more remarkably, rotenone-treated rats developed alpha-synuclein-positive cytoplasmic inclusions, similar to Lewy bodies, in nigral dopaminergic neurons – overcoming for the first time a key limitation of other available in vivo models. Moreover, rotenone provided the first proof-of-concept that a systemic defect in mitochondrial function could lead to selective nigrostriatal neurodegeneration. And although the rotenone model was developed initially to test the ‘mitochondrial hypothesis’ of PD, given the epidemiological links to pesticide exposure, it was also of interest that rotenone is a pesticide. Subsequent studies found that the rotenone model accurately recapitulates many other features of PD5, including: accumulation and aggregation of endogenous, wildtype alpha-synuclein; α-synuclein- and polyubiquitin-positive Lewy bodies and Lewy neurites; apomorphine-responsive behavioral deficits; early and sustained activation of microglia; oxidative modification and translocation of DJ-1 into mitochondria in vivo; impairment of the nigral ubiquitin-proteasome system; accumulation of iron in the substantia nigra through a mechanism involving transferrin and transferrin receptor 2; α-synuclein pathology in enteric neurons and functional deficits in GI function, including gastroparesis. Additionally, systemic rotenone treatment can recapitulate the retinal pathology, the loss of testosterone and some of the sleep disturbances that are typical of PD. It is also worth noting that the transferrin-dependent mechanism of iron accumulation discovered in the rotenone model was subsequently found to be operative in human PD6. In other words, the rotenone model predicted what would be found in PD. Further, after the initial work in rats, others reported successful application of the rotenone model in species that are more tractable genetically, including mice, Drosophila and C. elegans. It is also worth noting that, based on initial reports of rotenone neurotoxicity and the fact that it is a pesticide, epidemiological studies began to look at the potential role of exposure to rotenone per se as a risk factor for development of human PD. While the number of individuals exposed to rotenone and other ‘botanicals’ is small compared to other classes of synthetic pesticides, a recent study found an odds ratio of 5.9 (CI 0.6-56.1)7 and another found an odds ratio for rotenone of 10.9 (CI 2.5-48.0)8. Thus, the rotenone model informed subsequent epidemiological studies, which have suggested a potential role for rotenone in some cases of PD. For all its strengths, however, the rotenone model has limitations. As expected, this mitochondrial poison, like any other, can produce dose-dependent systemic toxicity and mortality. Moreover, especially when delivered by osmotic minipump, there has been substantial variability in the proportion of animals that become parkinsonian and in the extent of their nigrostriatal lesions. Despite this variability, many groups have reported that rotenone (2-3 mg/kg/day) produces selective nigrostriatal degeneration, generally without nonspecific lesions (e.g., see Fleming9). Nevertheless, for unclear reasons, a few labs have reported striatal or other lesions with systemic rotenone. For example, Cicchetti and colleagues (2004) found that rotenone caused “severe digestion problems” with a stomach that was enlarged and full of undigested food10. Although the authors may not have recognized it as such, this may have been the first indication that rotenone can reproduce gastrointestinal features of PD, such as gastroparesis. In fact, Drolet (2009) recently reported that rotenone accurately recapitulates pathological and functional features of parkinsonian gastrointestinal impairment11. Although the reasons for the discrepancies between labs are uncertain, recent refinements of the rotenone model have apparently made it more reproducible and have reduced nonspecific toxicities12. In the end, it is unrealistic to expect to be able to model perfectly in rats all aspects of an age-related disease like PD. Even genetically accurate models PD have met with limited success in replicating key behavioral and pathological features of the disease. Nevertheless, a great deal has been learned – and remains to be discovered – about pathogenic mechanisms using the rotenone model of PD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Oxidative stress and Parkinson’s disease
Blesa, J., Trigo-Damas, I., Quiroga-Varela, A., & Jackson-Lewis, V. R. (2015) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2015.00091 · Cited by 878
Obeso, J. A., Stamelou, M., Goetz, C. G., Poewe, W., Lang, A. E., Weintraub, D., Burn, D., Halliday, G. M., Bezard, E., Przedborski, S., et al. (2017) · Movement Disorders · doi:10.1002/mds.27115 · Cited by 859
“another environmental toxin associated with PD, also is a mitochondrial poison.(247,248) Second, in PD brains,”
Duty, S., & Jenner, P. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01426.x · Cited by 753
α-Synuclein binds to TOM20 and inhibits mitochondrial protein import in Parkinson’s disease
Di Maio, R., Barrett, P. J., Hoffman, E. K., Barrett, C. W., Zharikov, A., Borah, A., Hu, X., McCoy, J., Chu, C. T., Burton, E. A., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf3634 · Cited by 619
Self-citationLRRK2 activation in idiopathic Parkinson’s disease
Di Maio, R., Hoffman, E. K., Rocha, E. M., Keeney, M. T., Sanders, L. H., De Miranda, B. R., Zharikov, A., Van Laar, A., Stepan, A. F., Lanz, T. A., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aar5429 · Cited by 564
Self-citation
Metadata
- Authors
- Greenamyre, J. T., Cannon, J. R., Drolet, R., & Mastroberardino, P.-G.
- Venue
- Trends in Pharmacological Sciences
- Publisher
- Elsevier BV
- Published
- 2010-04
- Volume
- 31
- Issue
- 4
- Pages
- 141-142
- ISSN
- 0165-6147 (ISSN-L)
- OpenAlex
- W2024144670
- Cited by
- 166
- References
- 0
- FWCI
- 5.04
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lessons from the rotenone model of Parkinson's disease. https://app.cochat.ai/papers/10.1016/j.tips.2009.12.006
- The paper
- Greenamyre, J. T., Cannon, J. R., Drolet, R., & Mastroberardino, P.-G. (2010). Lessons from the rotenone model of Parkinson's disease. Trends in Pharmacological Sciences. https://doi.org/10.1016/j.tips.2009.12.006
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.